



2cureX's CEO Ole Thastrup appointed Adjunct Professor of Pharmacology & Drug Discovery at University of Copenhagen

Copenhagen, Denmark, 1 November 2007: 2cureX is pleased to announce that Ole Thastrup, CEO of 2cureX has been appointed Adjunct Professor of Pharmacology & Drug Discovery at the Department of Pharmacology and Pharmacotherapy, The Faculty of Pharmacy, University of Copenhagen.

“The university wishes with the appointment of Ole Thastrup as Adjunct Professor to appreciate a strong scientific effort of Ole Thastrup within the field of cellular signaling and development of highly innovative drug discovery technologies. Ole Thastrup has throughout his carrier operated in the interface between basic and applied research, and we look forward through the appointment to strengthen the interaction between Ole Thastrup and the university” said Arne Schousboe, Professor and Department Chair of the Department of Pharmacology and Pharmacotherapy, The Faculty of Pharmacy, University of Copenhagen.

“2cureX is pioneering a new technology named ChemoCellomics that for the first time allows screening of large numbers of drug candidates directly in cells from individual patients. To fully exploit this technology 2cureX is collaborating with the University Hospital and the University of Copenhagen where detailed disease and patient knowledge is available. It is our expectation that this joint effort will lead to a paradigm-shift in early drug discovery”, said Ole Thastrup.

Contacts:

Ole Thastrup
Chief Executive Officer

Tel: +45 45822036
e-mail: ot@2curex.com

Timm Jessen
Chief Business Officer

Tel: +49 (4315) 606 448
e-mail: tj@2curex.com

About 2cureX

- 2cureX is a Danish drug discovery company that rapidly generates drug candidates for the treatment of defined populations of cancer patients
- 2cureX is engaged in four oncology projects of which two have been commercially partnered
- 2cureX is leveraging its ChemoCellomics™ technology to merge identification of novel drugs with functional profiling of cancer cells from individual patients. The technology brings primary cancer cells from patients to the forefront of drug discovery
- 2cureX is developing its drug candidates together with clinical partners until proof of principle in man has been shown. Subsequent product development will be driven through partnerships with established pharmaceutical and biotechnology companies